Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 13 » Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence
Please verify you are not a robot.